News | May 14, 2025
GlaxoSmithKline Pharmaceuticals posts FY25 PAT at Rs. 915 Cr
The Board of Directors of the company recommends a final dividend of Rs. 42 per equity share for the 12 months period ended March 31, 2025
The Board of Directors of the company recommends a final dividend of Rs. 42 per equity share for the 12 months period ended March 31, 2025
The Protect VL project was born out of a vision to reduce the environmental footprint of medical devices
The CEP certification for Metformin Hydrochloride aligns with the company's strategy to penetrate stringently regulated markets
IGI recently completed the dose-escalation portion of its Phase 1 clinical study in patients with heavily pretreated multiple myeloma
Gelhaus has a proven track record of driving business growth
This outcome reflects Innoxel Lifesciences' ongoing commitment to maintaining the highest standards of quality, compliance, and regulatory excellence
The transaction enhances Roquette’s ability to deliver high-value drug delivery solutions to pharmaceutical customers worldwide
Breztri is an inhaled triple-combination therapy approved for the treatment of chronic obstructive pulmonary disease
This significant milestone enhances our global regulatory standing
This partnership marks a significant milestone in Sigachi's strategy to expand into advanced drug delivery technologies.
Subscribe To Our Newsletter & Stay Updated
